Literature DB >> 8439390

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.

H Tohgi1, T Abe, S Takahashi.   

Abstract

We studied the effects of L-threo-DOPS (L-DOPS) on the concentrations of total (conjugated and unconjugated) dopamine (DA) and norepinephrine (NE) in the cerebrospinal fluid (CSF) of parkinsonian patients with freezing phenomenon. The NE concentration increased remarkably and dose-dependently after administration of L-DOPS in both L-dopa/carbidopa-pretreated and untreated patients. The DA concentration also increased mildly but significantly in L-dopa/carbidopa-untreated patients. Freezing phenomenon improved in 6 out of 8 patients at Hoehn and Yahr's stage III, and 1 out of 5 patients at stage IV. These results indicate that L-DOPS administration increases the NE concentration dose-dependently, and is effective for freezing of gait of moderate severity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439390     DOI: 10.1007/bf02260912

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  20 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 3.  Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.

Authors:  Yan A Ivanenkov; Mark S Veselov; Nina V Chufarova; Alexander G Majouga; Anna A Kudryavceva; Alexandre V Ivachtchenko
Journal:  Mol Divers       Date:  2015-05-09       Impact factor: 2.943

4.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

5.  Quantitative Analysis of Catecholamines in the Pink1 -/- Rat Model of Early-onset Parkinson's Disease.

Authors:  Cynthia A Kelm-Nelson; Michael A Trevino; Michelle R Ciucci
Journal:  Neuroscience       Date:  2018-02-27       Impact factor: 3.590

6.  Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review.

Authors:  Katherine E McDonell; Cyndya A Shibao; Italo Biaggioni; Adam Hartman; David Robertson; Daniel O Claassen
Journal:  Cogn Behav Neurol       Date:  2019-09       Impact factor: 1.600

7.  Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients.

Authors:  Kelly A Mills; Zoltan Mari; Catherine Bakker; Vanessa Johnson; Gregory M Pontone; Alexander Pantelyat; Juan C Troncoso; Olga Pletnikova; Ted M Dawson; Liana S Rosenthal
Journal:  Parkinsonism Relat Disord       Date:  2016-09-25       Impact factor: 4.891

Review 8.  Pharmacological treatment in Parkinson's disease: Effects on gait.

Authors:  Katrijn Smulders; Marian L Dale; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak
Journal:  Parkinsonism Relat Disord       Date:  2016-07-17       Impact factor: 4.891

9.  The V81M variant of tyrosine hydroxylase is associated with more severe freezing of gait in Parkinson's disease.

Authors:  Izel Tekin; Nurgul Carkaci-Salli; Mechelle M Lewis; Richard B Mailman; Xuemei Huang; Kent E Vrana
Journal:  Parkinsonism Relat Disord       Date:  2015-12-23       Impact factor: 4.891

Review 10.  Non-dopaminergic treatments for motor control in Parkinson's disease.

Authors:  Susan H Fox
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.